Therapure Biopharma Inc. Announces Successful Health Canada Audit

Share Article

Therapure Biopharma Inc., an integrated Contract Development and Manufacturing Organization (CDMO), today announced that it has received a compliant rating from the Health Products and Food Branch Inspectorate of Health Canada.

Therapure Biopharma Inc., an integrated Contract Development and Manufacturing Organization (CDMO), today announced that it has received a compliant rating from the Health Products and Food Branch Inspectorate of Health Canada.

The rating results from a Good Manufacturing Practices (GMP) inspection conducted at Therapure’s facility during November 2011. The compliant rating means that the Company has successfully demonstrated that the aseptic fill/finish activities conducted in the facility as well as the associated support services are in compliance with the high standards of the Canadian Food and Drugs Act and its associated regulations. This detailed inspection covered Therapure’s vial, syringe and performed bag filling capabilities. Based on the results of the inspection, Therapure maintains it Establishment License and retains its ability to manufacture commercial products for existing and new clients in Canada and Europe.

In addition to being recognized in Canada, under the terms of the Mutual Recognition Agreement between Canada and the European Community and Australia, this Establishment License will be recognized by the European Medicines Agency (the EMA) and the Australian Therapeutic Goods Administration.

“The completion of the Health Canada inspection and the issuance of a compliant rating is confirmation of Therapure Biopharma’s ongoing commitment to maintaining quality systems to the highest global standard,” said Nick Green. “Quality is a cornerstone on which we build our business. As a company we strive to provide consistent performance, which is the key to maintaining the safety and effectiveness of every product that is manufactured resulting in the quality and reliability that is expected of a biologics manufacturing organization.”

As a result of achieving the compliant rating, Therapure will continue to provide formulation, filling, packaging, and testing services for approved biotherapeutic, prescription pharmaceutical, and plasma-derived biological products meeting the manufacturing outsourcing needs of the pharmaceutical and biotechnology industry.

About Therapure Biopharma:
Therapure Biobiopharma Inc. is an integrated CDMO that develops and manufactures (upstream and downstream processing) therapeutic proteins as well as provides aseptic fill/finish services for both complex biologics and small molecules. Therapure applies greater than 20 years of scientific and biologics manufacturing expertise to develop efficient and innovative solutions to advance products from discovery to market. Throughout the product development process, Therapure has the ability to provide these services in a fully scalable manner. Established development and manufacturing partnerships with a mixture of companies ranging from start-up to large multi-nationals has provided Therapure with a deep understanding of their client’s project specific needs. With its large, flexible, state-of-the-art facility as well as integrated services, Therapure can provide customer-focused manufacturing solutions giving clients the ability to stay within the same facility thereby reducing the time and cost of a technology transfer.
For more information, please visit: http://www.therapurebio.com

Therapure Contacts:

Dina Iezzi
Director, Marketing and Special Projects
(905) 286-6270
diezzi(at)therapurebio(dot)com

# # #

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Dina Iezzi
Visit website